Diagnose, treat, and prevent community acquired pneumonia using key recommendations from the IDSA/ATS CAP guidelines.
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
Researchers compared HAdV-3 with HAdV-7 replication kinetics and host response in ex vivo human lung tissue cultures.
There is a low incidence of second PJI in patients with bacteremia or hematogenous periprosthetic joint infection with concomitant prosthetic implants.
As SARS-CoV-2 has spread around the world, major health disparities have become apparent among patients with COVID-19, particularly in the Hispanic/Latinx community.
Investigators assessed patients who hospitalized with microbial S aureus bacteremia to determine the most meaningful cutoff point to define S aureus persistent bacteremia.
Researchers sought to determine whether individuals recovered from mildly symptomatic COVID-19 develop and sustain immunological memory against the SARS-CoV-2 virus.
Investigators analyzed a potential link between community-acquired Staphylococcus aureus bloodstream infection and increased short-term risk for myocardial infarction, which is associated with subsequent mortality.
The otic suspension is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid.